RxDoctor Payments Data

Keith Gottesdiener

Infectious Disease · Rahway, NJNPI 1821150376

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,121,544 of the $2,131,252 with a category attached, or 99.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 74.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $639,947 and has fallen 96.6% since, to $21,500 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,131,252in general payments, 2019–2025

Across 89 payments — averaging $23,947 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1.6M
  • Intercept Pharmaceuticals, Inc.$545K
  • Novo Nordisk AS$104
  • EMD Serono, Inc.$96

What the payments were for

  • Consulting fees$2,121,544100%
  • Travel & lodging$9,4330%
  • Food & beverage$2750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,131,252 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Other infectious disease in Rahway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →